Two months into 2026 and MedTech isn't playing around. Boston Scientific announced January 15 what is already the biggest deal of the year, a $14.5 billion agreement to acquire stroke-device maker Penumbra. Medtronic reported its best revenue growth in ten quarters. A Canadian startup got FDA clearance for the world's smallest intravascular camera. And if you make medical devices, there's a new set of quality rules in town that took effect on February 2nd. Welcome to Issue #1 of The MedTech Minute. Here's what you need to know.
Top Stories
Story 01
On January 15, Boston Scientific announced a definitive agreement to acquire Penumbra for approximately $14.5 billion, paying $374 per share in a mix of cash and stock. Penumbra makes thrombectomy and embolization devices for removing blood clots from vessels. The deal gives Boston Scientific a larger footprint in vascular surgery, a market with almost no overlap with its existing portfolio. The acquisition is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Why This Matters
At $14.5B, Boston Scientific is making a structural bet that vascular surgery will consolidate around platform builders. Penumbra was one of the last independent, large-scale thrombectomy pure-plays. Any standalone device company in the interventional neurovascular or peripheral vascular space now has a clearer exit path and a higher valuation ceiling.
M&A
$14.5B
Story 02
Medtronic reported its strongest enterprise revenue growth in ten quarters, driven entirely by its Cardiac Ablation Solutions business. PFA, a newer technique for treating atrial fibrillation that destroys abnormal tissue with electrical pulses instead of heat, grew 80% worldwide and 137% in the U.S. year-over-year. The company also completed the first U.S. soft-tissue surgery cases with its Hugo robotic system at Cleveland Clinic, opening a new competitive front against Intuitive Surgical.
Q3 Earnings
Cardiac
Story 03
Canada-based Vena Medical received FDA 510(k) clearance for its MicroAngioscope System, a device that provides full-color, live imaging directly inside peripheral blood vessels. The company calls it the world's smallest intravascular camera. More than 100 patients in Canada have already been treated with it. Vena simultaneously announced the opening of a new US$4.5 million manufacturing facility in Kitchener, Ontario, signaling it's ready to scale for the U.S. market.
FDA 510(k)
$4.5M Facility
Story 04
The FDA's Quality Management System Regulation (QMSR) took effect on February 2, 2026. It replaces the legacy Quality System Regulation by aligning U.S. requirements with ISO 13485:2016, the international quality standard most of the world already follows. For manufacturers already certified to ISO 13485, the path to compliance is shorter. For those who weren't, QMSR compliance is now a legal requirement, not a suggestion. Non-compliant device submissions face rejection.
Regulatory
QMSR
Know someone in MedTech? Forward this to a colleague. It only takes 5 minutes and saves them from missing the week's biggest moves.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $519.45 | ▲ 0.7% |
| SYK | Stryker | $354.60 | ▲ 1.3% |
| BDX | BD (Becton Dickinson) | $238.60 | ▼ 0.4% |
| JNJ | Johnson & Johnson | $157.20 | ▼ 0.6% |
| ABT | Abbott | $138.20 | ▼ 0.4% |
| ZBH | Zimmer Biomet | $110.40 | ▲ 0.8% |
| BSX ★ | Boston Scientific | $107.80 | ▲ 5.3% |
| GEHC | GE HealthCare | $91.80 | ▲ 0.4% |
| MDT | Medtronic | $88.40 | ▲ 2.1% |
| EW | Edwards Lifesciences | $68.30 | ▼ 1.1% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 2, 2026.
Deep Dive
295 AI/ML Devices Cleared in 2025, Here's What the Surge Means for MedTech in 2026
According to the FDA's CDRH database, a record 295 AI/ML-enabled medical devices were cleared in 2025. That's not a typo. For context: the agency cleared just 92 AI devices in 2021. (Source: FDA CDRH AI/ML device database) The growth isn't slowing, if anything, 2026 looks like it could exceed last year. Here's what's driving it and what it means for the industry.
- Radiology is still where most AI lives. Computer-aided detection and diagnosis tools for imaging, chest X-rays, mammograms, CT scans, make up the majority of cleared AI devices. The FDA is now considering exempting some radiology AI tools from requiring 510(k) clearance at all, which would accelerate adoption dramatically.
- Cardiac AI is the fastest-growing category. AI-powered ECG interpretation, arrhythmia detection, and image analysis are all seeing rapid clearances. The technology is moving from research to routine clinical use. Your next EKG might be read by software first.
- The bottleneck is shifting from clearance to reimbursement. Getting FDA clearance is now table stakes. Getting insurers to pay for AI-assisted reads, that's where companies are struggling. Centers for Medicare & Medicaid Services coverage decisions are the real gating factor in 2026.
Bottom line: AI in MedTech isn't a future trend, it's a current commercial reality. The companies that will win aren't necessarily the ones that get cleared fastest, but the ones that crack the reimbursement puzzle. Watch who's hiring health economics talent.
Industry Shifts
Shift 01
In addition to the Boston Scientific/Penumbra headline, Danaher has announced plans to acquire Masimo, a leader in patient monitoring and signal processing. The combination would give Danaher a significant presence in hospital monitoring alongside its existing diagnostics and life sciences tools business. Deal terms and timeline have not yet been fully confirmed, but sources indicate it values Masimo well above its recent market cap.
M&A
Shift 02
Johnson & Johnson has submitted its Ottava robotic surgery system to the FDA, bringing the three-way surgical robotics battle between Intuitive, Medtronic Hugo, and J&J Ottava into full swing. Medtronic already has clearance for Hugo's urology indication, and J&J's submission puts the market on notice that Intuitive's near-monopoly on soft-tissue robotic surgery is approaching its end.
Surgical Robotics
FDA Submission
Fun Fact & Trivia
Fun Fact
The first implantable cardiac pacemaker was tested in 1958 by Swedish surgeon Åke Senning, who implanted a device the size of a hockey puck into a 43-year-old patient. The battery lasted just a few hours. The patient went on to receive 26 more pacemaker implants over his lifetime, living until 2001 and reportedly attending the surgeon's retirement party.
MedTech Trivia
Which company's robotic surgery system has been used in more than 10 million procedures worldwide?
👇 Scroll to the footer for the answer
Sponsor
